Presentation
There are no effective pharmacological therapies for the core symptoms of autism, and the biological understanding of autism is poor. Research is hampered by a lack of biological models and clinical trials with diverse groups of people with autism
While new treatments have been developed, there is no European platform to test them clinically. The recent identification of genes associated with autism offers unique opportunities to remedy this situation.
The EU-AIMS consortium aims to undertake an integrated, translational effort to achieve key objectives in autism research. We have provided new tools and standards for clinical development to pave the way for a better quality of life for people with autism.
We have sought to harness these new developments to develop treatments based on our biological understanding of autism.
Project duration
6 years
|
Funding
20.5 millions €
|
Number of partners
48
|
Starting date
April 01, 2012
|
Coordinator : King's College London
Joliot Institute Contact: Vincent Frouin (vincent.frouin@cea.fr)
website :
https://www.eu-aims.eu/
H2020 agreement id : 115300
ABOUT IMI - INNOVATIVE MEDICINES INITIATIVE
IMI is the world's largest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
The objective of IMI, particularly in its second phase (IMI2, 2014-2020), is to develop new generation vaccines, drugs and treatments, such as new antibiotics.
For more information: https://www.imi.europa.eu/